Ensign Peak Advisors
AXSM icon

Ensign Peak Advisors’s Axsome Therapeutics AXSM Stock Holding History

Ensign Peak Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.43M Buy
18,091
+14,876
+463% +$3.23M 0.01% 588
2026
Q1 		$543K Sell
3,215
-15,630
-83% -$2.7M ﹤0.01% 940
2025
Q4 		$3.44M Sell
18,845
-5,500
-23% -$768K 0.01% 586
2025
Q3 		$2.96M Sell
24,345
-6,250
-20% -$704K ﹤0.01% 708
2025
Q2 		$3.19M Buy
30,595
+15,630
+104% +$1.66M 0.01% 746
2025
Q1 		$1.75M Buy
14,965
+400
+3% +$45.6K ﹤0.01% 959
2024
Q4 		$1.23M Hold
14,565
– – ﹤0.01% 1192
2024
Q3 		$1.31M Hold
14,565
– – ﹤0.01% 1165
2024
Q2 		$1.17M Hold
14,565
– – ﹤0.01% 1183
2024
Q1 		$1.16M Sell
14,565
-735
-5% -$61.7K ﹤0.01% 1220
2023
Q4 		$1.22M Hold
15,300
– – ﹤0.01% 1232
2023
Q3 		$1.07M Buy
15,300
+4,250
+38% +$318K ﹤0.01% 1144
2023
Q2 		$794K Buy
11,050
+1,100
+11% +$81.1K ﹤0.01% 1423
2023
Q1 		$614K Buy
9,950
+550
+6% +$36.1K ﹤0.01% 1575
2022
Q4 		$725K Buy
9,400
+750
+9% +$44.8K ﹤0.01% 1425
2022
Q3 		$386K Sell
8,650
-2,670
-24% -$133K ﹤0.01% 1590
2022
Q2 		$434K Hold
11,320
– – ﹤0.01% 1522
2022
Q1 		$469K Hold
11,320
– – ﹤0.01% 1574
2021
Q4 		$428K Buy
+11,320
New +$417K ﹤0.01% 1678
2021
Q3 		– Sell
-11,597
Closed -$782K – 1853
2021
Q2 		$782K Sell
11,597
-6,485
-36% -$389K ﹤0.01% 1499
2021
Q1 		$1.02M Hold
18,082
– – ﹤0.01% 1418
2020
Q4 		$1.47M Hold
18,082
– – ﹤0.01% 1222
2020
Q3 		$1.29M Buy
18,082
+10,826
+149% +$844K ﹤0.01% 1191
2020
Q2 		$597K Hold
7,256
– – ﹤0.01% 1424
2020
Q1 		$427K Buy
+7,256
New +$591K ﹤0.01% 1426

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ensign Peak Advisors's AXSM Position: Q2 2026 in Review

Ensign Peak Advisors increased its Axsome Therapeutics (AXSM) stake by 463% in Q2 2026, buying an estimated $3.23M and bringing the position to 18,091 shares worth $4.43M. The position accounts for 0.01% of the portfolio, ranked #588.

Ensign Peak Advisors first reported a position in AXSM in Q1 2020 and has held it in 25 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Ensign Peak Advisors held 18,091 shares of Axsome Therapeutics worth $4.43M as of Q2 2026.
  • Ensign Peak Advisors bought 14,876 Axsome Therapeutics shares in Q2 2026, an estimated $3.23M.
  • Axsome Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #588 holding.
  • Ensign Peak Advisors first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.